Here’s Why Puma Biotechnology Tanked 37.3% in November – Motley Fool

_______________________________________________________________________________________

To Receive daily job alerts, Enter your email address, and dont forget to verify the job alerts:

Delivered by FeedBurner


Motley Fool

Here's Why Puma Biotechnology Tanked 37.3% in November
Motley Fool
Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI), a biotechnology company in the middle of its first new drug launch, fell 37.3% in November, according to data from S&P Global Market Intelligence. Sales of Nerlynx appear to be leveling off before
Brokerages Set Puma Biotechnology Inc (PBYI) Price Target at $68.78Fairfield Current
Earnings Estimates Update: Puma Biotechnology Inc (NASDAQ:PBYI), The Medicines Company (NASDAQ:MDCO)StandardOracle
Puma Biotechnology Inc (NYSE:PBYI) Institutional Investors Q2 2018 SentimentThorold News
Richland Standard –MoneyMakingArticles –The EN Bulletin
all 8 news articles »